Download PHS 398 (Rev. 11/07), Biographical Sketch Format

Program Director/Principal Investigator (Last, First, Middle):
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
WALL, Nathan R.
Assistant Professor of Biochemistry, Pediatrics and
Radiation Medicine
eRA COMMONS USER NAME
NAWALL
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
Walla Walla College, College Place, WA
Walla Walla College, College Place, WA
Wayne State University, Detroit, MI
Yale University, New Haven, CT
University of Massachusetts, Worcester, MA
Harvard Medical School, Boston, MA
University of Redlands, Redlands, CA
DEGREE
(if applicable)
YEAR(s)
FIELD OF STUDY
B.S.
M.S.
Ph.D.
Postdoc
Postdoc
Postdoc
M.B.A.
1991
1995
2000
2001-02
2002
2003-04
2008
Biology
Biology
Cancer Biology
Cancer Biology
Cancer Biology
Molecular Biology
Business (management)
A. Positions and honors
Positions and Employment
2001-02
Postdoctoral Associate, Department of Pathology, Boyer Center for Molecular Medicine, Yale
University, New Haven, CT (with Dario C. Altieri, M.D.).
2002-02
Postdoctoral Fellow, Department of Cancer Biology & Cancer Center, University of
Massachusetts, Worcester, MA (with Dario C. Altieri, M.D.).
2003-04
Postdoc Fellow, Dept. of Path., Harvard Med. School, Boston, MA (with Yang Shi, Ph.D.).
2004-2006
Member, Center for Molecular Biology and Gene Therapy, LLUSM.
2004-present
Assistant Professor. Depts. Biochemistry/Microbiology, and Medicine, LLUSM.
2006-present
Founding Member, Center for Health Disparities Research & Mol. Med., LLUSM.
2008-2009
1st Lieutenant, California Army National Guard
2009-present
Captain, California Army National Guard
2011-present
Biochemistry, Graduate Program Director, Loma Linda University
Awards and Professional Activities
1998
Graduate Student Professional Travel Award (July 12, 1998)
1998
AACR special workshop: “Molecular Biology and Pathology of Neoplasia”, Keystone, CO.
July 12-19, 1998. AACR assoc. membership and 1-year subscription to Cancer Research.
1998
The Detroit Physiological Society Award.
1997-99
National Institute of Health Training Grant (CA-09531-11)
2000
Graduate Student Professional Travel Award (April 1, 2000)
2003
AACR-Bristol-Myers Squibb Oncology Scholar-in-Training Award (94th Annual Meeting, July
2003)
2002-04
Individual National Research Service Award (NRSA), National Institutes of Health/ National
Cancer Institute, Priority Score 138 (F32 CA97802)
2002-04
Carrol Small Basic Science Faculty Development Award (August 1, 2002- July 31, 2004)
2005-2006
Hirshberg Foundation for Pancreatic Cancer Research Fellow
2007
MBRS Support of Competitive Research (SCORE) review panel, 2008/01 Council ZGM1
MBRS-7 CC, 10/01/2007, Lisa Dunbar, SRA.
2008-2010
N.I.H. Health Disparities Loan Repayment Program (LRP) Award, 08/01/08.
2008
National Defense Service Medal (United States Army)
2009
Army Service Ribbon (United States Army)
2010-2012
N.I.H. Health Disparities Loan Repayment Program (LRP) Award, 08/09/10.
2010-2013
Alumni Board of Directors, University of Redlands, Redlands, CA
PHS 398/2590 (Rev. 11/07)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
B. Selected peer-reviewed publications (in chronological order)
1. Mohammad RM, Katato K, Almatchy VP, Wall N, Liu K-Z, Schultz CP, Mantsch HH, Varterasian M, AlKatib A. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2chlorodeoxyadenosine: preclinical studies. Clinical Cancer Research, 4(2): 445-453, 1998.
2. Mohammad RM, Pettit GR, Almatchy VP, Wall N, Varterasian M, Al-Katib A. Synergistic interaction of
selected marine animal products against human diffuse large cell lymphoma. Anti-Cancer Drugs, 9(2): 2129, 1998.
3. Mohammad RM, Beck FWJ, Katato K, Hamdy N, Wall N, Al-Katib A. Potentiation of 2chlorodeoxyadenosine activity by bryostatin 1 in resistant B-CLL cell line: association with increased ratios
of dCK/5’-NT and Bax/Bcl-2. Biological Chemistry, 379(10): 1253-1261, 1998.
4. Lian F, Bhuiyan M, Li Y, Wall N, Kraut M, Sarkar FH. Genistein-induced G2-M arrest, p21waf1 upregulation,
and apoptosis in a non-small-cell lung cancer cell line. Nutrition and Cancer, 31(3): 184-191, 1998.
5. Mohammad RM, Limvarapuss C, Hamdy N, Dutcher BS, Beck FWJ, Choudhuri R, Wall NR, Al-Katib AM.
Treatment of De Novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Int J Oncol, 14(5): 945-950, 1999.
6. Mohammad RM, Limvarapuss C, Wall NR, Hamdy N, Beck FWJ, Pettit GR, Al-Katib A. A new tubulin
polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom’s
macroglobulinemia xenograft model. Int J Oncol, 15(2): 367-372, 1999.
7. Wall NR, Mohammad RM, Al-Katib AM. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin
agents is important for the susceptibility to drug-induced apoptosis in the human early pre-B acute
lymphoblastic leukemia cell line, reh. Leukemia Research, 23(10): 881-888, 1999.
8. Wall NR, Mohammad RM, Nabha SM, Pettit GR, Al-Katib AM. Modulation of cIAP-1 by novel antitubulin
agents when combined with bryostatin 1 result in increased apoptosis in the human early pre-B acute
lymphoblastic leukemia cell line, reh. Biochem Biophys Res Commun, 266(1): 76-80, 1999.
9. Wall NR, Mohammad RM, Reddy KR, Al-Katib AM. Bryostatin 1 induces the ubiquitination and
proteasome degradation of Bcl-2 in the human early pre-B acute lymphoblastic leukemia cell line, reh. Int J
Mol Med, 5(2):165-171, 2000.
10. Beck FWJ, Al-Katib AM, Ahmad I, Wall NR, Liu KZ, Mantsch HH, Mohammad RM. Bryostatin 1-induced
modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells. Int J Mol Med,
5(4):341-347, 2000.
11. Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriquez DH, Eilender DS,
Murgo A, Wall N, Al-Katib AM. Phase II trial of bryostatin 1 in patients with relapsed low grade nonHodgkin’s lymphoma and chronic lymphocytic leukemia. Clinical Cancer Research, 6:825-828, 2000.
12. Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al-Katib AM. Effects of Combretastatin A-4 prodrug
against a panel of malignant human B-lymphoid cell lines. Anticancer Drugs, 11(5):385-392, 2000.
13. Mohammad RM, Wall NR, Dutcher J, Al-Katib A. The addition of bryostatin 1 to CHOP chemotherapy
improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clinical
Cancer Research, 6(12):4960-4956, 2000.
14. Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Sulkini BM, Pettit GR, Al-Katib AM. Evaluation of
combretastatin a-4 prodrug in non-Hodgkin’s lymphoma xenograft model: preclinical efficacy. Anticancer
Drugs, 12(1):57-63, 2001.
15. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J
Clinical Invest., 108(7):981-990, 2001.
16. Wall NR, Mohammad RM, Al-Katib AM. Mitogen-activated protein kinase is required for bryostatin 1induced differentiation of the human acute lymphoblastic leukemia cell line reh. Cell Growth &
Differentiation, 12(12):641-647, 2001.
17. Wall NR, Beck FWJ, Al-Katib AM, Mohammad RM. Treatment-induced expression of anti-apoptotic
proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line. J Drug Targeting, 9(5):329-339,
2001.
18. Fortugno P, Wall NR, Giodini A, O’Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC, Altieri DC.
Survivin wxists in immunochemically distinct subcellular pools and is involved in spindle microtubule
function. J Cell Science, 115(3):575-585, 2002.
19. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M, Altieri DC. Regulation of
microtubule stability and mitotic timing by survivin. Cancer Res., 62(9):2462-2467, 2002.
PHS 398/2590 (Rev. 11/07)
Page
Continuation Format Page
Program Director/Principal Investigator (Last, First, Middle):
20. Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD. Induction and
regulation of Tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in
renal cell carcinoma. Cancer Res., 62(11):3093-3099, 2002.
21. O’Connor DS, Wall NR, Plescia J, Porter ACG, Altieri DC. A p34cdc2 survival checkpoint in cancer. Cancer
Cell, 2(1):43-54, 2002.
22. Zhang Y, Mohammad R, Rishi AK, Farhana L, Dawson MI, Feng K, Leid M, Peterson V, Zhang X,
Edelstein M, Eilander D, Biggar S, Wall N, Reichert U, Fontana JA. Induction of apoptosis of human BCLL and ALL cells by a novel retinoid and its non-retinoidal analog. Blood, 100(8):2917-2925, 2002.
23. Wall NR, O’Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on
Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res., 63(1):230-235, 2003.
24. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin
pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis.
Clin Cancer Res., 9(7):2683-2692, 2003.
25. Wall NR, Shi Y. Small RNA: can RNA interference be exploited for therapy? Lancet, 362(9393): 14011403, 2003.
26. Chen J, Wall NR, Kocher K, Duclos N, Shi Y, Gilliland DG. Stable expression of small interfering RNA
sensitizes TEL-PDGFßR to inhibition with imatinib or rapamycin. J Clin Invest., 113(12):1784-1791, 2004.
27. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, deCabo R,
Sinclair DA. Calorie restriction promotes mammalian cell survival by inducing SIRT1 deacetylase. Science.
305(5682):390-392, 2004. Epub Science Express 2004 Jun 17.
28. Sui G, Affar EB, Shi Y, Brignone C, Wall NR, Yin P, Donohoe M, Calvo D, Luke MP, Grossman SR, Shi Y.
Yin Yang 1 is a negative regulator of p53 in vivo. Cell, 117(7):859-872, 2004.
29. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes
tumorigenesis. J Clin Invest., 114(8):1117-1127, 2004.
30. Kalla-Singh S, Moretta D, Almaguel F, Wall NR, De Leon M, De Leon D. Differential effect of ProIGF-II
and IGF-II on Resveratrol Induced Cell Death by Regulating Survivin Cellular Localization and
Mitochondrial Depolarization in Breast Cancer Cells. Growth Factors, 25(6):363-372, 2007.
31. Parrish YK, Baez I, Milford TA, Benitez A, Galloway N, Rogerio JW, Sahakian E, Kagoda M, Huang G, Hao
Q, Sevilla Y, Barsky LW, Zielinska E, Price MA, Wall NR, Dovat S, Payne KJ. IL-7 Dependence in Human
B Lymphopoiesis Increases During Progression of Ontogeny from Cord Blood to Bone Marrow. AcceptedThe Journal of Immunology, 182(7):4255-4266, 2009.
32. Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, Acevedo-Martinez S, De Leon M, Langridge W,
Wall NR. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and
metastatic potential. British Journal of Cancer 100(7):1073-1086, 2009.
33. Neidigh J, Darwanto A, Williams A, Wall NR, Sowers L. Cloning and characterization of Rhodotorula
glutinis thymine hydroxylase. Chemical Research in Toxicology 22(5):885-893, 2009.
34. Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall
NR, Lilly MB, De Leon M, and Casiano CA. Docetaxel-induced prostate cancer cell death involves
concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer,
8(68):1-15, 2009.
35. Galloway NR, Aspe JR, Sellers C, Wall NR. Enhanced antitumor effect of combined gemcitabine and
proton radiation in the treatment of pancreatic cancer. Pancreas 38(7):782-790, 2009.
36. Asumen MG, Ifeacho TV Cockerham L, Pfandl C, and Wall NR. Dynamic changes to survivin subcellular
localization are initiated by DNA damage. OncoTargets and Therapy, 3:129-137, 2010.
37. Rios SS, Andrade RV, Pereira RW, Wall NR, Bahjri K, Caldas E, Cavalcante L, Figueiredo FC.
Microsatellite instability in endometrial polyps. Eur J Obstet Gynecol Reprod Biol., 153 (2): 193-197, 2010.
38. Odumosu O, Payne K, Baez I, Jutzy J, Wall N, Langridge W. Suppression of Dendritic Cell Activation by
Diabetes Autoantigens Linked to the Cholera Toxin B Subunit. Immunobiology, 2010 Sep 24, Epub.
39. Aspe JR and Wall NR. Survivin-T34A: molecular mechanism and therapeutic potential. OncoTargets and
Therapy, 2010 Dec 3, Accepted for Publication. (Review)
40. Khan S, Jutzy JMS, Aspe JR, McGregor D, Neidigh JW, Wall NR. Survivin is released from cancer cells
via exosomes. Apoptosis, 16(1): 1-12, 2011.
PHS 398/2590 (Rev. 11/07)
Page
Continuation Format Page
Program Director/Principal Investigator (Last, First, Middle):
RESEARCH PROJECTS ONGOING OR COMPLETED DURING THE LAST THREE YEARS
Current
NIH/NCMHD 1P20MD001632
09/30/05-06/30/10
LLU Center for Health Disparities Research (PI, Marino De Leon; Co-I, Nathan R. Wall)
Project #3: “Oxidative stress-induced cellular pathways in pancreatic cancer” (PI, Wall)
Under no cost extension.
Complete
National Medical Test Bed (NMTB) / Department of the Army DAMD 17-97-2-7016
“Survivin in the tumor microenvironment” (PI, Wall)
02/19/09-05/30/10
Hirshberg Foundation for Pancreatic Cancer Research
Survivin Regulation of Apoptosis in Pancreatic Cancer” (PI, Wall)
11/15/05-11/14/06
NIH; Type: F32 CA097802
“Survivin Regulation of Apoptosis” (PI, Wall)
09/01/02-08/31/04
PHS 398/2590 (Rev. 11/07)
Page
Continuation Format Page